Status:
COMPLETED
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.
Eligibility Criteria
Inclusion
- Type 2 diabetes
- HbA1c over 7%
- No contraindication with NovoMix® 70
Exclusion
- Type 1 diabetes
- Subjects participating in a clinical trial or another observational study
- Subjects under previous basis-bolus insulin therapy
- Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
619 Patients enrolled
Trial Details
Trial ID
NCT00704223
Start Date
May 1 2008
End Date
November 1 2008
Last Update
June 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna, Austria, 1140